Bionyra Pharma, a clinical-stage biopharmaceutical company focused on next-generation biologics for severe immunological and inflammatory diseases, emerged from stealth after raising an oversubscribed $165 million Series A. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from Sanofi Ventures, Arkin Bio, and other investors. The company is co-founded by Frédéric Marrache, MD, PhD, and the financing includes board appointments for key investors, indicating the new venture’s intent to drive pipeline decisions from an early stage. The announcement also frames the strategy around differentiated immunology and target/pathway mapping. For the market, the launch adds fresh competition in inflammatory biologics and highlights continued capital formation despite a selective funding environment across the broader biotech sector.